Neutralization of tumour necrosis factor (TNF) but not of IL‐1 reduces inflammation in chronic dextran sulphate sodium‐induced colitis in mice
暂无分享,去创建一个
W. Falk | D. Männel | F. Obermeier | V. Gross | T. Andus | J. Schölmerich | G. KOJOUHAROFF | W. HANS | F. OBERMEIER | D. N. MA¨NNEL | T. ANDUS | J. SCHO¨LMERICH | V. GROSS | W. FALK | G. Kojouharoff | W. Hans | D. N. MA¨NNEL | J. SCHO¨LMERICH
[1] A. Feller,et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene , 1993, Cell.
[2] R. Coffman,et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. , 1994, Immunity.
[3] A. Mantovani,et al. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. , 1994, Immunology today.
[4] C. Fiocchi,et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. , 1995, Journal of immunology.
[5] D. Remick,et al. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. , 1992, Journal of immunology.
[6] D. Remick,et al. Antiserum to Tumor Necrosis Factor and Failure to Prevent Murine Colitis , 1995, Journal of pediatric gastroenterology and nutrition.
[7] A. Munakata,et al. The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. , 1995, Journal of gastroenterology.
[8] S. Targan,et al. Triggered human mucosal T cells release tumour necrosis factor‐alpha and interferon‐gamma which kill human colonic epithelial cells , 1991, Clinical and experimental immunology.
[9] K. Rajewsky,et al. Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.
[10] P. Simon,et al. Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease. , 1990, Gut.
[11] S. Waugh,et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. , 1991, Journal of immunology.
[12] A. Cooke,et al. Tumour necrosis factor‐alpha and interferon‐gamma production measured at the single cell level in normal and inflamed human intestine , 1990, Clinical and experimental immunology.
[13] A. Baldwin,et al. Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids , 1995, Science.
[14] M. Neurath,et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice , 1995, The Journal of experimental medicine.
[15] A. Baldwin,et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. , 1995, Science.
[16] Y. Mahida,et al. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. , 1989, Gut.
[17] K. Mitsuyama,et al. IL‐8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease , 1994, Clinical and experimental immunology.
[18] S. Schreiber,et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. , 1993, Clinical and experimental immunology.
[19] H. Towbin,et al. Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. , 1993, Clinical and experimental rheumatology.
[20] C. Nast,et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. , 1990, The Journal of clinical investigation.
[21] C. Beglinger,et al. Platelets in ulcerative colitis and Crohn's disease express functional interleukin‐1 and interleukin‐8 receptors , 1994, European journal of clinical investigation.
[22] D. Hommes,et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). , 1995, Gastroenterology.
[23] A. Levine,et al. Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity. , 1996, Gastroenterology.
[24] B. Echtenacher,et al. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. , 1990, Journal of immunology.
[25] B. Echtenacher,et al. Critical protective role of mast cells in a model of acute septic peritonitis , 1996, Nature.
[26] M. Feldmann,et al. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.